1 / 27

Raphael Sandaltzopoulos, PhD , MBA Professor at MBG (Molecular Biology) rmsandal@mbg.duth.gr

Lab. of Gene Expression, Molecular Diagnosis and Modern Therapeutics, MBG, DUTH. BIOMARKERS DISCOVERY: An introduction. Raphael Sandaltzopoulos, PhD , MBA Professor at MBG (Molecular Biology) rmsandal@mbg.duth.gr. What is a Biomarker?.

ssussman
Télécharger la présentation

Raphael Sandaltzopoulos, PhD , MBA Professor at MBG (Molecular Biology) rmsandal@mbg.duth.gr

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Lab. of Gene Expression, Molecular Diagnosis and Modern Therapeutics, MBG, DUTH BIOMARKERS DISCOVERY: An introduction Raphael Sandaltzopoulos, PhD, MBA Professor at MBG (Molecular Biology) rmsandal@mbg.duth.gr

  2. What is a Biomarker? Biomarker is a measured characteristic which may be used as an indicator of a certain biological state or condition. Biomarker is a measured characteristic which may be used as an indicator of a certain biological state or condition. Biomarker is a measured characteristic which may be used as an indicator of a certain biological state or condition. Biomarker is a measureable characteristic which may be used as an indicator of a certain biological state or condition. Measureable: ease of sampling, reliability, reproducibility and accuracy of detection method. Indicator: robust correlation with biological condition.

  3. A good Biomarker shows a robust correlation with a certain biological condition. Difference of average: Is a value of a parameter significantly different among two groups which are defined by the value of a second parameter? Pearson correlation: How tightly does the value of one parameter correlate with the value of another parameter?

  4. Example of difference of average (one or two-tailed t-test) Expression of T-lymphocyte markers (mRNA) is a reliable indicator of CD8+ T-lymphocyte infiltration in ovarian tumors CD3 staining CD8 staining

  5. TTF1 is overexpressed in TIL+ Epithelial Ovarian Cancer • ttf1 mRNA was quantified by qPCR in 45 ovarian tumors (classified as TIL+ or TIL-). • mRNA levels were higher in TIL+ compared to TIL- samples (p=0.039).

  6. Example of Pearson correlation analysis TTF1 expression correlates with T-cell infiltration • qPCR analysis of the relative expression of ttf1 and cd8a mRNA in 96 ovarian cancer samples, verified a significant correlation (Pearson correlation=0.329, p<0.01).

  7. TMEM132D is over-expressed in TIL+ Epithelial Ovarian Cancer Example of Pearson correlation analysis TMEM132D: Single-pass type I transmembrane protein. May serve as a cell-surface marker for oligodendrocyte differentiation. Implicated in anxiety disorders. 95% Confidence Interval: If we were to repeat the sampling 100 times and calculate a population of 100 r values, the population mean would probably lie between 0.747 and 0.923 95% of the time, the confidence intervals contain the true mean.

  8. Common pitfalls of correlation analysis Correlation and causality: a. Correlation does not necessarily imply causality.

  9. Common pitfalls of correlation analysis Correlation and causality: b. Normal distribution and lack of correlation does not necessarily imply independence. X and Y are uncorrelated; Both have the same normal distribution; X and Y are not independent.

  10. Common pitfalls of correlation analysis Correlation and linearity: c. Correlation does not necessarily imply linearity Four sets of data with the same correlation of 0.816

  11. The nature of a Biomarker

  12. Adapted from Kaiser J, 2010. Science 330:576.

  13. Technology platforms commonly used in Biomarkers’ Discovery

  14. In silico Biomarkers Biomarkers discovered by data analysis and mining workflows and algorithms capable of working with disparate data resources in the areas of gene expression, copy number, pathway networks, miRNA, and metabolomics data, next generation sequencing (NGS) data including RNA-seq, ChIP-seq, whole genome, exome, and others, using advanced bioinformatics modeling and development of analytics. http://icbi.georgetown.edu/in-silico/#sthash.E7RqMyt6.dpuf

  15. The biomarker evolution pathway in translational medicine

  16. An example of Risk Score Assessment of microRNA Biomarkers in NSCLC Risk score = 0,969 x miR486 + 0,973 x miR30d - 0,650 x miR1 - 0,815 miR499 Adapted from Zander et al, 2011, Clin. Cancer Res 11:3360.

  17. A “good” Biomarker has a great combination of sensitivity and specificity Sensitivity: The fraction of people with the disease that the test correctly identifies as positive. Specificity: The fraction of people without the disease that the test correctly identifies as negative.

  18. Receiver Operating Characteristic (ROC) curve A receiver operating curve (ROC) is a plot of sensitivity versus 1-specificity. The name is derived from its original use in radar technology. The dotted line represents a useless test that has no discriminatory power. The size of the area between the dotted line and the solid line in the ROC curve reflects the ability of a test to discriminate between diseased and non-diseased individuals across the range of potential cut-offs.

  19. Area Under Curve (A.U.C.) as a measure of a Biomarker’s usefulness Large distribution of measured values between the diseased and the non-diseased populations make it easy to choose a cut off value. Small difference in distribution of measured values between the diseased and the non-diseased populations make it very difficult to choose a cut off value. Test value

  20. Serum concentration of endothelial markers 81 patients, 46 benign 27 healthy women * - p<0,05; ** - p<0,01; *** - p<0,001.

  21. Validation in an independent group of patients 117 patients, 59 benign * - p<0,05; ** - p<0,01; *** - p<0,001.

  22. ROC analysis: better Diagnostics by combination of biomarkers

  23. Receiver Operating Characteristic (ROC) curve The cutoff value is chosen to minimize missing true positives, thus including more false positives. (for example: when consequences of missing a case are serious, e.g. testing potential blood donors for HIV). Cutoff value chosen at statistical mean. Equal number of true positive missed as the number of people diagnosed as false positive. Cutoff value chosen to minimize inclusion of false positives. (for example when treatment is expensive or invasive). Setting the criterion value is a compromise between sensitivity and specificity. Test value

  24. The Kaplan-Meier estimator for the survival function from lifetime data. Used to measure the fraction of patients living for a certain amount of time after treatment. A Kaplan–Meier plot of the survival function is a series of horizontal steps of declining magnitude which, when a large enough sample is taken, approaches the true survival function for the population.

  25. Sectors of Biomarkers applications in medicine

  26. Biomarkers in personalized treatment

  27. Qualities of a good Biomarkers in diagnosis and therapy Discrimination of healthy/deseased speciments (sensitivity and specificity). Easily detectable and quantifiable. Simple (not a combination of many factors). Extracellular (secreted) or cell surface. Presence/expression in a restricted tissue, cell type as a result of a certain condition. Minimal influence by irrelevant factors. Consistent behavior within a population.

More Related